Plain-English translation of NCT04111978 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a medication called letrozole as a maintenance treatment—meaning a long-term preventive therapy—after you've completed chemotherapy and surgery for ovarian, fallopian tube, or peritoneal cancer. Letrozole works by blocking estrogen, a hormone that can fuel certain types of these cancers. Half of the participants will receive letrozole daily, and half will receive a placebo (a pill with no medication), to see if this medication helps keep cancer from coming back.
Many ovarian cancers grow in response to estrogen. This medication has been very successful in preventing breast cancer recurrence in patients whose tumors are estrogen-sensitive, but it hasn't been thoroughly tested in ovarian cancer. This trial aims to find out whether this medication can work the same way—stopping ovarian cancer from returning—and improve long-term survival.
You likely qualify if…
You likely don't qualify if…
You will take one tablet by mouth every day for up to 5 years (or until the medication causes unacceptable side effects or your cancer progresses). You'll have follow-up visits every 12 weeks for the first 2 years, then every 24 weeks for the remaining 3 years. At these visits, your doctor will check how you're doing, assess any side effects, and monitor your health using questionnaires about quality of life. You'll be randomly assigned to either receive the active medication or a placebo, and neither you nor your doctor will know which one you're taking until the trial ends.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
Austria